A detailed history of Grimes & Company, Inc. transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, Grimes & Company, Inc. holds 42,675 shares of IRWD stock, worth $171,553. This represents 0.01% of its overall portfolio holdings.

Number of Shares
42,675
Previous 37,759 13.02%
Holding current value
$171,553
Previous $328,000 15.24%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 22, 2024

BUY
$5.58 - $8.61 $27,431 - $42,326
4,916 Added 13.02%
42,675 $278,000
Q1 2024

Apr 17, 2024

SELL
$8.32 - $15.45 $11,489 - $21,336
-1,381 Reduced 3.53%
37,759 $328,000
Q4 2023

Jan 24, 2024

SELL
$8.79 - $11.51 $8,007 - $10,485
-911 Reduced 2.27%
39,140 $447,000
Q1 2023

Apr 20, 2023

SELL
$10.37 - $12.56 $80,834 - $97,905
-7,795 Reduced 16.29%
40,051 $421,000
Q3 2022

Oct 28, 2022

BUY
$10.14 - $12.38 $11,711 - $14,298
1,155 Added 2.47%
47,846 $496,000
Q2 2022

Jul 22, 2022

SELL
$11.05 - $12.72 $67,681 - $77,910
-6,125 Reduced 11.6%
46,691 $538,000
Q1 2022

May 06, 2022

BUY
$10.61 - $12.88 $49,697 - $60,329
4,684 Added 9.73%
52,816 $664,000
Q4 2021

Feb 01, 2022

BUY
$10.86 - $13.95 $130 - $167
12 Added 0.02%
48,132 $561,000
Q3 2021

Nov 08, 2021

BUY
$11.92 - $13.92 $34,830 - $40,674
2,922 Added 6.46%
48,120 $628,000
Q2 2021

Aug 04, 2021

BUY
$10.16 - $13.11 $47,721 - $61,577
4,697 Added 11.6%
45,198 $582,000
Q1 2021

May 12, 2021

BUY
$9.04 - $11.86 $239,505 - $314,218
26,494 Added 189.15%
40,501 $453,000
Q3 2020

Nov 12, 2020

BUY
$8.99 - $10.74 $23,571 - $28,160
2,622 Added 23.03%
14,007 $126,000
Q2 2020

Jul 31, 2020

SELL
$9.14 - $11.97 $52,235 - $68,408
-5,715 Reduced 33.42%
11,385 $117,000
Q3 2019

Nov 05, 2019

BUY
$8.59 - $10.96 $146,889 - $187,416
17,100 New
17,100 $146,000

Others Institutions Holding IRWD

About IRONWOOD PHARMACEUTICALS INC


  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $616M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track This Portfolio

Track Grimes & Company, Inc. Portfolio

Follow Grimes & Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grimes & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Grimes & Company, Inc. with notifications on news.